Jump directly to main navigation Jump directly to content Jump to sub navigation

Crimean-Congo Haemorrhagic Fever Vaccine.Short title: CCHFVaccine

INNT

Duration: 07/2017 - 12/2022

Funding: EU Horizon Program

 

The aim of the CCHFVaccine project is to develop a vaccine to prevent Crimean Congo Hemorrhagic Fever Virus (CCHFV) infections in humans and animals worldwide. The project partners (Karolinaska University, Heath Protection England Inst. Virology of the University of Giessen, Friedrich-Loeffler-Institut, NIH Hamilton, Paul-Ehrlich-Institut and others) represent a multidisciplinary research network capable of delivering vaccine candidates, methods and procedures for clinical trials, with a particular focus on prevention. The consortium has unique experimental capabilities available for this task to fill the gaps in CCHFV research in immunology and vaccinology. To achieve this overall goal, an intensive work plan will be addressed with the following specific objectives: i) produce vaccine candidates, ii) establish and validate animal models, iii) identify promising vaccine candidates for clinical trials and analyze their immune-mediated protection, v) conduct phase clinical trials and ensure a strategy for effective introduction and use in resource-poor countries, and vi) bring this project to public health organizations and industry. This CCHFVaccine project involves BSL-4 high-security laboratories (state of the art) and the only BSL-4 laboratory in the EU with large animal infection capabilities. Experienced scientists are working in these facilities regarding the development and evaluation of vaccine candidates, involvement of authorities responsible for human and animal health protection. Clinical samples from endemic countries and an international network are available, which has already proven successful in previous EU-funded CCHFever and EDENext projects.

Further information can be found on the project page
https://www.cchfvaccine.eu/

Involved INNT scientists:

Dr. Markus Keller
Dr. Kerstin Fischer
Prof. Dr. Martin H. Groschup

Dr. Matthew Pickin (PostDoc)

['']

[''] LogoCCHFVaccine, © InsermTransfert

Projekt partners:

Prof. Ali Mirazimi
Public Health Agencyof Sweden (Folkhalmsomyndigheten), Stockholm und Östersund, Schweden
https://www.folkhalsomyndigheten.se/

Prof. Dr. Friedemann Weber
Justus-Liebig-Universität, Gießen, Deutschland
https://www.uni-giessen.de/index.html

Prof. Roger Hewson
Department of Health, London, England
https://www.gov.uk/government/organisations/department-of-health-and-social-care

Prof. Matti Sällberg
Karolinska Institutet, Stockholm, Schweden
https://ki.se/en

Prof. Dr. Veronika von Messling
Paul-Ehrlich-Institut (PEI), Langen, Deutschland
https://www.pei.de/DE/home/home-node.html

Dr. Iva Christova
National Center of Infectiousand Parasitic Diseases (NCIPD), Sofia, Bulgarien
https://www.ncipd.org/index.php?option=com_k2&view=item&id=190:about-ncipd&Itemid=1191&lang=en

Dr. Anna Boitard
Inserm Transfert (IT), Lyon, Frankreich
https://www.inserm-transfert.fr/?lang=2

Dr. Isme Humolli
National Institute of Public Health, Kosovo
http://www.niph-kosova.org

Prof. Nazif Elaldi
Cumhuriyet Universitesi, Sivas, Türkei
https://www.cumhuriyet.edu.tr/

Prof. Zati Vatansever
Kafkas Universitesi, Kars, Türkei
https://www.kafkas.edu.tr/kau/en

Dr. Rickaurd Knutsson
Statens Veterinärmedicinska Anstalt, Uppsala, Schweden
https://www.sva.se/en

Prof. Dr. Heinrich Feldmann
National Institute of Health, Rockville Pike, Maryland, USA
https://www.nih.gov/

Dr. Farida Tishkova
Tajik Research Institute of Preventive Medicine, Dushanbe, Tajikistan
http://www.istc.int/en/institute/10220#